董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher A. Viehbacher | 男 | President, Chief Executive Officer and Director | 64 | 3048.86万美元 | 0.70 | 2024-02-14 |
| Stephen A. Sherwin | 男 | Director | 75 | 43.52万美元 | 1.78 | 2024-02-14 |
| Jesus B. Mantas | 男 | Director | 55 | 41.77万美元 | 0.51 | 2024-02-14 |
| Susan Langer | -- | Director | -- | 未披露 | 0.05 | 2024-02-14 |
| Monish Patolawala | -- | Director | -- | 未披露 | 未持股 | 2024-02-14 |
| William A. Hawkins | 男 | Director | 70 | 41.02万美元 | 0.42 | 2024-02-14 |
| Caroline D. Dorsa | 女 | Director and Chair of the Board | 64 | 42.52万美元 | 2.32 | 2024-02-14 |
| Eric K. Rowinsky | 男 | Director | 67 | 41.02万美元 | 1.97 | 2024-02-14 |
| Maria C. Freire | 女 | Director | 69 | 41.38万美元 | 0.21 | 2024-02-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher A. Viehbacher | 男 | President, Chief Executive Officer and Director | 64 | 3048.86万美元 | 0.70 | 2024-02-14 |
| Robin C. Kramer | 女 | Senior Vice President, Chief Accounting Officer | 58 | 未披露 | 未持股 | 2024-02-14 |
| Rachid Izzar | 男 | Executive Vice President, Global Product Strategy and Commercialization | 49 | 未披露 | 0.97 | 2024-02-14 |
| Nicole Murphy | 女 | Executive Vice President, Pharmaceutical Operations and Technology | 51 | 492.97万美元 | 0.96 | 2024-02-14 |
| Priya Singhal | 女 | Executive Vice President, Head of Development | 56 | 未披露 | 未持股 | 2024-02-14 |
| Jane Grogan | -- | Executive Vice President, Head of Research | 57 | 未披露 | 未持股 | 2024-02-14 |
| Adam Keeney | 男 | Executive Vice President, Head of Corporate Development | 47 | 未披露 | 未持股 | 2024-02-14 |
| Susan H. Alexander | 女 | Executive Vice President, Chief Legal Officer | 67 | 679.02万美元 | 5.17 | 2024-02-14 |
| Michael R. McDonnell | 男 | Executive Vice President and Chief Financial Officer | 60 | 720.98万美元 | 1.94 | 2024-02-14 |
| Ginger Gregory | 女 | Executive Vice President and Chief Human Resources Officer | 56 | 508.03万美元 | 未持股 | 2024-02-14 |
董事简历
中英对照 | 中文 | 英文- Christopher A. Viehbacher
-
Christopher A. Viehbacher，经验丰富，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
Christopher A. Viehbacher, has served as Biogen Inc. President and Chief Executive Officer and member of Biogen Inc. Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhouseCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previously served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., and Crossover Health. He is also a trustee of Northeastern University and a member of the board of fellows at Stanford Medical School. - Christopher A. Viehbacher，经验丰富，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
- Christopher A. Viehbacher, has served as Biogen Inc. President and Chief Executive Officer and member of Biogen Inc. Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhouseCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previously served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., and Crossover Health. He is also a trustee of Northeastern University and a member of the board of fellows at Stanford Medical School.
- Stephen A. Sherwin
-
Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。
Stephen A. Sherwin,currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as an advisory partner with Third Rock Ventures, LLC. He previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company's merger with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. In addition, Dr. Sherwin previously served on the Board of Directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011. - Stephen A. Sherwin自2015年9月以来，Sherwin一直担任Neon Therapeutics, Inc.的董事会成员。Sherwin博士是旧金山加利福尼亚大学的临床医学教授，扎克伯格旧金山综合医院血液肿瘤科的一名志愿者主治医师。Sherwin博士目前也是Third Rock的风险合伙人，也是帕克癌症免疫治疗研究所科学指导委员会的成员。Sherwin博士曾于2001年担任Ceregene，Inc.的联合创始人和董事长，直到2013年被Sangamo Biosciences，Inc.收购。在此之前，Sherwin博士于1990年担任Cell Genesys，Inc.的董事长兼首席执行官，这是一家癌症免疫治疗公司，直到2009年与ANI Pharmaceuticals合并，公司前身为BioSante Pharmaceuticals，Inc.舍温博士还是安进公司于2006年收购的抗体公司Abgenix的联合创始人和董事长。舍温博士在过去五年中目前在Aduro Biotech，Inc.、Biogen，Inc.和Neurocrine Biosciences，Inc.的董事会任职，Sherwin博士还担任BiangnTe制药公司的董事，直到与阿尼制药公司合并，在2013个RigelP药学公司，VICA公司和VelaSTEM公司。Sherwin博士持有哈佛医学院的医学博士，以及生物学学士学位，来自耶鲁大学的优等生。
- Stephen A. Sherwin,currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as an advisory partner with Third Rock Ventures, LLC. He previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company's merger with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. In addition, Dr. Sherwin previously served on the Board of Directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011.
- Jesus B. Mantas
-
Jesus B. Mantas 是负责IBM业务转型服务部门的全球管理合伙人，他还负责IBM咨询企业发展。Mantas先生是IBM执行绩效团队、IBM执行技术团队和IBM主席加速团队的成员，并且是IBM西班牙裔多元化委员会的名誉主席。他在世界经济论坛的全球人工智能委员会和HITEC的董事会任职，HITEC是一家专注于发展和推进西班牙裔高管在科技行业职业生涯的非营利组织。他是Benhamou Global Ventures Fund IV的有限合伙人，Benhamou Global Ventures Fund IV是一家专注于数字化转型的早期公司的投资基金，并且是西班牙裔主导的早期公司的积极投资者。从2002年到2016年，Mantas先生领导IBM的商业咨询部门，该部门是世界上最大的咨询机构之一。此前，他曾担任IBM全球流程服务和业务服务部门在拉丁美洲的领导职务，此前他曾担任北美副总裁的多个领导职位。在加入IBM之前，Mantas先生是普华永道咨询公司的合伙人、加州大学欧文分校管理研究生院的兼职教授和西班牙空军的一名军官。
Jesus B. Mantas,serves as the Global Managing Partner responsible for IBM Business Transformation Services unit of IBM, and he is also responsible for IBM Consulting Corporate Development. Mr. Mantas is a member of the IBM Executive Performance Team, IBM Executive Technology Team and IBM Chairman Acceleration Team and is the Emeritus Chair of the IBM Hispanic Diversity Council. He served in the Global AI Council of the World Economic Forum, serves on the board of HITEC, a non-profit organization focused on developing and advancing the careers of Hispanic executives in the Technology Industry and on the board of NACME (National Action Council for Minorities in Engineering). He is a limited partner to Benhamou Global Ventures Fund IV, an investment fund for early-stage companies focusing on digital transformation, and is an active investor in Hispanic-led early stage companies. From 2002 through 2016, Mr. Mantas led IBM's Business Consulting unit, one of the largest consulting organizations in the world. Prior roles included leading IBM Global Process Services and the Business Services unit in Latin America after he held multiple leadership positions as Vice President in North America. Before joining IBM, Mr. Mantas was a Partner in PricewaterhouseCoopers Consulting, an adjunct professor at University of California Irvine – Graduate School of Management and an officer in the Air Force of Spain. - Jesus B. Mantas 是负责IBM业务转型服务部门的全球管理合伙人，他还负责IBM咨询企业发展。Mantas先生是IBM执行绩效团队、IBM执行技术团队和IBM主席加速团队的成员，并且是IBM西班牙裔多元化委员会的名誉主席。他在世界经济论坛的全球人工智能委员会和HITEC的董事会任职，HITEC是一家专注于发展和推进西班牙裔高管在科技行业职业生涯的非营利组织。他是Benhamou Global Ventures Fund IV的有限合伙人，Benhamou Global Ventures Fund IV是一家专注于数字化转型的早期公司的投资基金，并且是西班牙裔主导的早期公司的积极投资者。从2002年到2016年，Mantas先生领导IBM的商业咨询部门，该部门是世界上最大的咨询机构之一。此前，他曾担任IBM全球流程服务和业务服务部门在拉丁美洲的领导职务，此前他曾担任北美副总裁的多个领导职位。在加入IBM之前，Mantas先生是普华永道咨询公司的合伙人、加州大学欧文分校管理研究生院的兼职教授和西班牙空军的一名军官。
- Jesus B. Mantas,serves as the Global Managing Partner responsible for IBM Business Transformation Services unit of IBM, and he is also responsible for IBM Consulting Corporate Development. Mr. Mantas is a member of the IBM Executive Performance Team, IBM Executive Technology Team and IBM Chairman Acceleration Team and is the Emeritus Chair of the IBM Hispanic Diversity Council. He served in the Global AI Council of the World Economic Forum, serves on the board of HITEC, a non-profit organization focused on developing and advancing the careers of Hispanic executives in the Technology Industry and on the board of NACME (National Action Council for Minorities in Engineering). He is a limited partner to Benhamou Global Ventures Fund IV, an investment fund for early-stage companies focusing on digital transformation, and is an active investor in Hispanic-led early stage companies. From 2002 through 2016, Mr. Mantas led IBM's Business Consulting unit, one of the largest consulting organizations in the world. Prior roles included leading IBM Global Process Services and the Business Services unit in Latin America after he held multiple leadership positions as Vice President in North America. Before joining IBM, Mr. Mantas was a Partner in PricewaterhouseCoopers Consulting, an adjunct professor at University of California Irvine – Graduate School of Management and an officer in the Air Force of Spain.
- Susan Langer
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Monish Patolawala
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- William A. Hawkins
-
William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及the University of Minnesota Foundation的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
William A. Hawkins,serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation, an interventional cardiology company. Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves on the boards of Virtue Labs, Cereius, Enterra, Cirtec Medical Corp., Baebies, Inc. and Immucor, all of which are life science companies. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. He has a dual degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia's Darden School of Business. - William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及the University of Minnesota Foundation的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
- William A. Hawkins,serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation, an interventional cardiology company. Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves on the boards of Virtue Labs, Cereius, Enterra, Cirtec Medical Corp., Baebies, Inc. and Immucor, all of which are life science companies. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. He has a dual degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia's Darden School of Business.
- Caroline D. Dorsa
-
Caroline D. Dorsa 2009年4月到现在担任PSEG的执行副总裁和首席财务官；2009年4月到现在担任执行副总裁和首席财务官（动力）；2009年4月到现在担任执行副总裁和首席财务官（PSE＆G）；2009年4月到现在担任首席财务官（能源控股）；2009年4月到现在担任执行副总裁和首席财务官（服务）；2008年1月到2009年4月担任全球人类健康策略和集成（默克股份有限公司）的高级副总裁；2007年11月到2008年1月担任高级副总裁和首席财务官（Gilead科学股份有限公司）；2007年2月到2007年11月担任高级副总裁首席财务官（Avaya股份有限公司）。
Caroline D. Dorsa,EVP and CFO, Public Service Enterprise Group, Inc. (2009 – 2015);SVP of Global Human Health, Strategy and Integration, Merck & Co., Inc. (2008 – 2009);SVP and CFO, Gilead Sciences, Inc. (2007 – 2008);EVP and CFO, Avaya, Inc. (2007);Various financial and operational positions at Merck & Co., Inc. including Vice President and Treasurer (1987 – 2007).B.A. in History from Colgate University;MBA in Finance and Accounting from Columbia University. - Caroline D. Dorsa 2009年4月到现在担任PSEG的执行副总裁和首席财务官；2009年4月到现在担任执行副总裁和首席财务官（动力）；2009年4月到现在担任执行副总裁和首席财务官（PSE＆G）；2009年4月到现在担任首席财务官（能源控股）；2009年4月到现在担任执行副总裁和首席财务官（服务）；2008年1月到2009年4月担任全球人类健康策略和集成（默克股份有限公司）的高级副总裁；2007年11月到2008年1月担任高级副总裁和首席财务官（Gilead科学股份有限公司）；2007年2月到2007年11月担任高级副总裁首席财务官（Avaya股份有限公司）。
- Caroline D. Dorsa,EVP and CFO, Public Service Enterprise Group, Inc. (2009 – 2015);SVP of Global Human Health, Strategy and Integration, Merck & Co., Inc. (2008 – 2009);SVP and CFO, Gilead Sciences, Inc. (2007 – 2008);EVP and CFO, Avaya, Inc. (2007);Various financial and operational positions at Merck & Co., Inc. including Vice President and Treasurer (1987 – 2007).B.A. in History from Colgate University;MBA in Finance and Accounting from Columbia University.
- Eric K. Rowinsky
-
Eric K. Rowinsky担任执行副总裁、首席医疗官以及研发部负责人。Rowinsk博士先前在英克隆系统公司（ImClone Systems）担任首席医疗管。Rowinsk博士在临床试验管理领域以及肿瘤类药物研发领域具有超过25年的经验，包括使爱必妥（Erbitux）通过食品及药物管理局（Food and Drug Administration）认证的工作，其中用于治疗脑、颈以及结肠癌；以及通过临床开发，推进其他8种生物疗法。以上工作都是在英克隆系统公司完成的。他还在各类癌症疗法药物的研发以及注册上起到积极作用，上述疗法药物包括紫杉醇、多烯紫杉醇、伊立替康、拓扑替康、埃罗替尼、吉非替尼、帕尼单抗、拉帕替尼以及西罗莫司脂化物。Rowinsky博士目前在百健艾迪（Biogen IDEC）股份有限公司以及其他上市生物制药公司董事会工作，同时踏实纽约州大学医学院的副教授。他在约翰·霍普金斯医院完成了内科肿瘤研究项目。Rowinsky博士是约翰·霍普金斯医院肿瘤科副教授，随后成为临床研究负责人以及癌症疗法与研究中心（Cancer Therapy and Research Center）药物研发协会（Institute for Drug Development）的董事，该中心位于在德克萨斯州圣安东尼。
Eric K. Rowinsky,professional career has been focused on the development and registration of new therapeutics of all types. He has played an integral role and has led teams that have registered more than twelve novel therapies for patients with advanced cancers. He has been an independent consultant to the biopharmaceutical industry since 2010. Dr. Rowinsky has served as President of Inspirna, Inc., a privately-held life sciences company, since November 2015 and previously served as its Executive Chairman from December 2016 to September 2021. He has served as Chief Medical Officer of Hummingbird Biotherapeutics, a private life-science company focusing on discovery of novel targets and protein therapeutics for cancer and autoimmune diseases from January 2020 to March 2023. From June 2016 to June 2021, he served as the Chief Scientific Officer of Clearpath Development Inc., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015, he was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells and rare diseases. Prior to that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Inc, a life sciences company. From 1996 to 2004 he held several positions at the Cancer Therapy & Research Center's Institute for Drug Development, including Director of the Institute and Director of Clinical Research. From 1988 to 1996 he was an Associate Professor of Oncology at the Johns Hopkins School of Medicine. Dr. Rowinsky has also served on the Board of Scientific Counselors of the National Cancer Institute. - Eric K. Rowinsky担任执行副总裁、首席医疗官以及研发部负责人。Rowinsk博士先前在英克隆系统公司（ImClone Systems）担任首席医疗管。Rowinsk博士在临床试验管理领域以及肿瘤类药物研发领域具有超过25年的经验，包括使爱必妥（Erbitux）通过食品及药物管理局（Food and Drug Administration）认证的工作，其中用于治疗脑、颈以及结肠癌；以及通过临床开发，推进其他8种生物疗法。以上工作都是在英克隆系统公司完成的。他还在各类癌症疗法药物的研发以及注册上起到积极作用，上述疗法药物包括紫杉醇、多烯紫杉醇、伊立替康、拓扑替康、埃罗替尼、吉非替尼、帕尼单抗、拉帕替尼以及西罗莫司脂化物。Rowinsky博士目前在百健艾迪（Biogen IDEC）股份有限公司以及其他上市生物制药公司董事会工作，同时踏实纽约州大学医学院的副教授。他在约翰·霍普金斯医院完成了内科肿瘤研究项目。Rowinsky博士是约翰·霍普金斯医院肿瘤科副教授，随后成为临床研究负责人以及癌症疗法与研究中心（Cancer Therapy and Research Center）药物研发协会（Institute for Drug Development）的董事，该中心位于在德克萨斯州圣安东尼。
- Eric K. Rowinsky,professional career has been focused on the development and registration of new therapeutics of all types. He has played an integral role and has led teams that have registered more than twelve novel therapies for patients with advanced cancers. He has been an independent consultant to the biopharmaceutical industry since 2010. Dr. Rowinsky has served as President of Inspirna, Inc., a privately-held life sciences company, since November 2015 and previously served as its Executive Chairman from December 2016 to September 2021. He has served as Chief Medical Officer of Hummingbird Biotherapeutics, a private life-science company focusing on discovery of novel targets and protein therapeutics for cancer and autoimmune diseases from January 2020 to March 2023. From June 2016 to June 2021, he served as the Chief Scientific Officer of Clearpath Development Inc., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015, he was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells and rare diseases. Prior to that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Inc, a life sciences company. From 1996 to 2004 he held several positions at the Cancer Therapy & Research Center's Institute for Drug Development, including Director of the Institute and Director of Clinical Research. From 1988 to 1996 he was an Associate Professor of Oncology at the Johns Hopkins School of Medicine. Dr. Rowinsky has also served on the Board of Scientific Counselors of the National Cancer Institute.
- Maria C. Freire
-
Maria C. Freire， 2012年11月至2021年9月，她担任the Foundation for the National Institutes of Health的总裁、执行董事和董事会成员。从2008年3月到2012年11月，她担任the Albert and Mary Lasker Foundation的总裁和董事会成员。加入Lasker Foundation之前，她曾担任the Global Alliance for TB Drug Development的总裁兼首席执行官（2001年至2008年），以及the National Institutes of Health的技术转移办公室主任（1995年至2001年）。她曾任职于许多国家和国际组织的董事会，包括美国食品和药物管理局科学委员会、世界卫生组织知识产权、创新和公共卫生委员会以及联合国秘书长药品获取问题高级别小组。她还担任Koneksa Health（一家私营公司，开发、测试和验证用于临床试验的数字生物标志物）的董事会成员。她也是美国国家医学院和外交关系委员会的成员，她是许多奖项的获得者，包括2017年Gold Stevie Award“年度女性”，美国卫生和人类服务部部长杰出服务奖，Arthur S. Fleming奖和Bayh-Dole奖。她持有the University of Virginia的生物物理学博士学位，以及the Universidad Peruana Cayetano Heredia（位于Lima, Peru。）的学士学位。
Maria C. Freire,has served as a director since April 2012. From November 2012 until September 2021, Dr. Freire served as the President and Executive Director, and a member of the board of directors, of The Foundation for the National Institutes of Health ("FNIH"), a Congressionally authorized independent organization that draws together the world's foremost researchers and resources in support of the mission of the National Institutes of Health ("NIH"). Prior to her appointment to the FNIH, Dr. Freire was the President and a member of the board of directors of the Albert and Mary Lasker Foundation, a non-profit organization that bestows the Lasker Awards in basic and clinical science and advocates for medical research. From 2001 to 2008, Dr. Freire served as President and Chief Executive Officer of the Global Alliance for TB Drug Development, a public-private partnership that develops better, faster-acting, and affordable drugs to fight tuberculosis. An expert in technology commercialization, she directed the Office of Technology Transfer at the NIH from 1995 to 2001 and served as a commissioner on the World Health Organization's Commission on Intellectual Property Rights, Innovation and Public Health. Dr. Freire obtained her Bachelor of Science degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, and her PhD in Biophysics from the University of Virginia; she completed post-graduate work in Immunology and Virology at the University of Virginia and the University of Tennessee. She is currently a director at Exelixis, Inc. (NASDAQ: EXEL), Biogen (NASDAQ: BIIB), and Koneksa Health Inc. She has previously served on the Science Board of the Food and Drug Administration and as a member of the Commission on a Global Health Risk Framework for the Future of the Institute of Medicine, among others. Her awards include the Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Flemming Award, the Bayh-Dole Award, the 2017 Washington Business Journal's "Women Who Mean Business" Award, the 2017 Gold Stevie Award for "Woman of the Year," and NonProfit PRO's 2019 "Executive of the Year" Award. Dr. Freire is a member of the U.S. National Academy of Medicine and the Council on Foreign Relations. - Maria C. Freire， 2012年11月至2021年9月，她担任the Foundation for the National Institutes of Health的总裁、执行董事和董事会成员。从2008年3月到2012年11月，她担任the Albert and Mary Lasker Foundation的总裁和董事会成员。加入Lasker Foundation之前，她曾担任the Global Alliance for TB Drug Development的总裁兼首席执行官（2001年至2008年），以及the National Institutes of Health的技术转移办公室主任（1995年至2001年）。她曾任职于许多国家和国际组织的董事会，包括美国食品和药物管理局科学委员会、世界卫生组织知识产权、创新和公共卫生委员会以及联合国秘书长药品获取问题高级别小组。她还担任Koneksa Health（一家私营公司，开发、测试和验证用于临床试验的数字生物标志物）的董事会成员。她也是美国国家医学院和外交关系委员会的成员，她是许多奖项的获得者，包括2017年Gold Stevie Award“年度女性”，美国卫生和人类服务部部长杰出服务奖，Arthur S. Fleming奖和Bayh-Dole奖。她持有the University of Virginia的生物物理学博士学位，以及the Universidad Peruana Cayetano Heredia（位于Lima, Peru。）的学士学位。
- Maria C. Freire,has served as a director since April 2012. From November 2012 until September 2021, Dr. Freire served as the President and Executive Director, and a member of the board of directors, of The Foundation for the National Institutes of Health ("FNIH"), a Congressionally authorized independent organization that draws together the world's foremost researchers and resources in support of the mission of the National Institutes of Health ("NIH"). Prior to her appointment to the FNIH, Dr. Freire was the President and a member of the board of directors of the Albert and Mary Lasker Foundation, a non-profit organization that bestows the Lasker Awards in basic and clinical science and advocates for medical research. From 2001 to 2008, Dr. Freire served as President and Chief Executive Officer of the Global Alliance for TB Drug Development, a public-private partnership that develops better, faster-acting, and affordable drugs to fight tuberculosis. An expert in technology commercialization, she directed the Office of Technology Transfer at the NIH from 1995 to 2001 and served as a commissioner on the World Health Organization's Commission on Intellectual Property Rights, Innovation and Public Health. Dr. Freire obtained her Bachelor of Science degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, and her PhD in Biophysics from the University of Virginia; she completed post-graduate work in Immunology and Virology at the University of Virginia and the University of Tennessee. She is currently a director at Exelixis, Inc. (NASDAQ: EXEL), Biogen (NASDAQ: BIIB), and Koneksa Health Inc. She has previously served on the Science Board of the Food and Drug Administration and as a member of the Commission on a Global Health Risk Framework for the Future of the Institute of Medicine, among others. Her awards include the Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Flemming Award, the Bayh-Dole Award, the 2017 Washington Business Journal's "Women Who Mean Business" Award, the 2017 Gold Stevie Award for "Woman of the Year," and NonProfit PRO's 2019 "Executive of the Year" Award. Dr. Freire is a member of the U.S. National Academy of Medicine and the Council on Foreign Relations.
高管简历
中英对照 | 中文 | 英文- Christopher A. Viehbacher
Christopher A. Viehbacher，经验丰富，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
Christopher A. Viehbacher, has served as Biogen Inc. President and Chief Executive Officer and member of Biogen Inc. Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhouseCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previously served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., and Crossover Health. He is also a trustee of Northeastern University and a member of the board of fellows at Stanford Medical School.- Christopher A. Viehbacher，经验丰富，Viehbacher先生自2022年11月起担任Biogen Inc.总裁兼首席执行官、Biogen Inc.董事会成员。在加入Biogen之前，Viehbacher先生曾于2015年至2022年担任总部位于波士顿的投资基金Gurnet Point Capital的管理合伙人。在此之前，Viehbacher先生于2008年至2014年担任赛诺菲全球首席执行官。在加入Sanofi之前，Viehbacher先生在德国、加拿大、法国的GlaxoSmithKline工作了20多年，后来又在美国担任北美制药部门的总裁。Viehbacher先生的职业生涯始于普华永道会计师事务所，并取得了特许会计师资格。Viehbacher先生曾在Vedanta Biosciences，Inc.、Before Brands，Inc.和Crossover Health担任董事会主席。他也是东北大学的董事和斯坦福医学院的研究员委员会成员。上市公司PureTech Health Plc董事会成员。教育，加拿大安大略省Queen's University学士。
- Christopher A. Viehbacher, has served as Biogen Inc. President and Chief Executive Officer and member of Biogen Inc. Board of Directors since November 2022. Prior to joining Biogen, Mr. Viehbacher served as Managing Partner of Gurnet Point Capital, a Boston based investment fund from 2015 to 2022. Prior to that, Mr. Viehbacher served as Global CEO of Sanofi, from 2008 to 2014. Prior to joining Sanofi, Mr. Viehbacher spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Mr. Viehbacher began his career with PricewaterhouseCoopers LLP and qualified as a chartered accountant. Mr. Viehbacher previously served on the board of directors of Vedanta Biosciences, Inc. as chair, BEFORE Brands, Inc., and Crossover Health. He is also a trustee of Northeastern University and a member of the board of fellows at Stanford Medical School.
- Robin C. Kramer
Robin C. Kramer，她曾一直担任Hertz Holdings and Hertz公司的高级副总裁兼首席会计官（2014年5月以来）。加入Hertz Holdings and Hertz公司之前，她曾担任Deloitte & Touche公司的审计合伙人（从2007年到2014年），包括任职Deloitte公司的国家机关的会计标准和通信集团（从2007年到2010年）。从2005年到2007年，她曾担任Fisher Scientific International公司的首席会计官。从2004年到2005年，她曾担任the Gillette Company的外部报告、会计和控制董事。她也曾担任Ernst & Young公司、Arthur Andersen公司的公共会计公司的合伙人。她持有Salem State College in Massachusetts的会计学士学位。她是马萨诸塞、纽约和康涅狄格注册会计师。她是the Massachusetts Society of CPAs、the AICPA的成员，也担任马萨诸塞州州会计委员会（the Massachusetts State Board of Accountancy）的董事会成员。
Robin C. Kramer,has served as Biogen Inc. Senior Vice President, Chief Accounting Officer since December 2020. Prior to that, Ms. Kramer served as Biogen Inc. Vice President, Chief Accounting Officer from November 2018 to December 2020. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Andersen LLP. Ms. Kramer is a licensed CPA in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs. Ms. Kramer currently serves on the board of directors of the Center for Women and Enterprise. Ms. Kramer previously served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015 and Probus Insurance Company Europe DAC from 2016 to 2018.- Robin C. Kramer，她曾一直担任Hertz Holdings and Hertz公司的高级副总裁兼首席会计官（2014年5月以来）。加入Hertz Holdings and Hertz公司之前，她曾担任Deloitte & Touche公司的审计合伙人（从2007年到2014年），包括任职Deloitte公司的国家机关的会计标准和通信集团（从2007年到2010年）。从2005年到2007年，她曾担任Fisher Scientific International公司的首席会计官。从2004年到2005年，她曾担任the Gillette Company的外部报告、会计和控制董事。她也曾担任Ernst & Young公司、Arthur Andersen公司的公共会计公司的合伙人。她持有Salem State College in Massachusetts的会计学士学位。她是马萨诸塞、纽约和康涅狄格注册会计师。她是the Massachusetts Society of CPAs、the AICPA的成员，也担任马萨诸塞州州会计委员会（the Massachusetts State Board of Accountancy）的董事会成员。
- Robin C. Kramer,has served as Biogen Inc. Senior Vice President, Chief Accounting Officer since December 2020. Prior to that, Ms. Kramer served as Biogen Inc. Vice President, Chief Accounting Officer from November 2018 to December 2020. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Andersen LLP. Ms. Kramer is a licensed CPA in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs. Ms. Kramer currently serves on the board of directors of the Center for Women and Enterprise. Ms. Kramer previously served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015 and Probus Insurance Company Europe DAC from 2016 to 2018.
- Rachid Izzar
Rachid Izzar，自2021年7月起担任阿尔茨海默氏病和痴呆症业务部的执行副总裁。在此之前，伊扎尔先生曾担任Biogen Inc.洲际地区的总裁，该地区包括拉丁美洲、澳大利亚、亚洲、日本、中东和非洲、土耳其和俄罗斯，以及全球生物原生物仿制药部门。在加入Biogen之前，伊扎尔是阿斯利康在法国的国家总裁，他的职责包括领导商业和制造业务。在阿斯利康任职期间，他担任过许多职务，包括心血管专营权的全球副总裁。在此之前，Izzar曾担任战略转型副总裁、上海首席执行官中国投资组合副总裁、中国、澳大利亚、巴西、俄罗斯、拉丁美洲、亚洲、土耳其、中东和非洲商业国际副总裁。舍布鲁克大学工商管理硕士。哈佛商学院，企业高管转型计划。
Rachid Izzar,has served as Biogen Inc. Executive Vice President, Head of Global Product Strategy and Commercialization since July 2021. Prior to that Mr. Izzar served as Biogen Inc. President for the Intercontinental Region, which includes Latin America, Australia, Asia, Japan, the Middle East and Africa, Turkey and Russia, and the Global Biogen Biosimilars Unit. Prior to joining Biogen, Mr. Izzar was a Country President for AstraZeneca in France, where his responsibilities included leadership for commercial and manufacturing operations. He held numerous roles at his time with AstraZeneca, including the position of Global Vice President of the Cardiovascular Franchise where he contributed significantly to the development of the franchise within the North American subsidiary, as well as in Europe and China. Prior to that, Mr. Izzar was Vice President Strategic Transformation, also, China Portfolio for CEO based in Shanghai and Vice President Commercial International covering China, Australia, Brazil, Russia, America Latin, Asia, Turkey, the Middle East and Africa.- Rachid Izzar，自2021年7月起担任阿尔茨海默氏病和痴呆症业务部的执行副总裁。在此之前，伊扎尔先生曾担任Biogen Inc.洲际地区的总裁，该地区包括拉丁美洲、澳大利亚、亚洲、日本、中东和非洲、土耳其和俄罗斯，以及全球生物原生物仿制药部门。在加入Biogen之前，伊扎尔是阿斯利康在法国的国家总裁，他的职责包括领导商业和制造业务。在阿斯利康任职期间，他担任过许多职务，包括心血管专营权的全球副总裁。在此之前，Izzar曾担任战略转型副总裁、上海首席执行官中国投资组合副总裁、中国、澳大利亚、巴西、俄罗斯、拉丁美洲、亚洲、土耳其、中东和非洲商业国际副总裁。舍布鲁克大学工商管理硕士。哈佛商学院，企业高管转型计划。
- Rachid Izzar,has served as Biogen Inc. Executive Vice President, Head of Global Product Strategy and Commercialization since July 2021. Prior to that Mr. Izzar served as Biogen Inc. President for the Intercontinental Region, which includes Latin America, Australia, Asia, Japan, the Middle East and Africa, Turkey and Russia, and the Global Biogen Biosimilars Unit. Prior to joining Biogen, Mr. Izzar was a Country President for AstraZeneca in France, where his responsibilities included leadership for commercial and manufacturing operations. He held numerous roles at his time with AstraZeneca, including the position of Global Vice President of the Cardiovascular Franchise where he contributed significantly to the development of the franchise within the North American subsidiary, as well as in Europe and China. Prior to that, Mr. Izzar was Vice President Strategic Transformation, also, China Portfolio for CEO based in Shanghai and Vice President Commercial International covering China, Australia, Brazil, Russia, America Latin, Asia, Turkey, the Middle East and Africa.
- Nicole Murphy
Nicole Murphy，自2022年2月起担任Biogen Inc.制药运营和技术执行副总裁。在此之前，Murphy女士曾在Biogen担任高级管理职务，最近于2019年6月至2022年1月担任Biogen Inc.高级副总裁兼全球制造与技术运营主管。2017年，Murphy女士在Biogen血友病专营权的成功分拆过程中发挥了关键作用，担任Bioverativ的副总裁兼技术运营主管，负责临床和商业开发、质量、监管、制造和采购。在分拆之前，Murphy女士于2015年5月至2016年12月担任百健公司的总经理兼剑桥网站运营主管。在加入Biogen之前，Murphy女士是生物制药公司Amgen的执行董事兼供应链主管，她的职责包括领导商业制造和技术运营。2001-2015年，Murphy女士在安进任职期间还担任过许多技术和业务职务，为各种设施初创企业、业务发展整合、战略转型和新产品推出做出了重大贡献。在加入安进公司之前，Murphy女士在Immunex制药公司和孟山都公司担任过各种工艺开发和工程职位。学历：Massachusetts Amherst大学B.S. Engineering分校，工学学士；伦斯勒理工学院，工学硕士，工商管理硕士。
Nicole Murphy,has served as Biogen Inc. Executive Vice President, Pharmaceutical Operations and Technology since February 2022. Prior to that, Ms. Murphy has held senior executive positions at Biogen, including most recently as Biogen Inc. Senior Vice President, Head of Global Manufacturing & Technical Operations, from June 2019 to January 2022. In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen's hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ responsible for clinical and commercial development, quality, regulatory, manufacturing and procurement. Prior to the spin-off Ms. Murphy was the General Manager and Head of Cambridge Site Operations at Biogen from May 2015 to December 2016. Prior to joining Biogen, Ms. Murphy was Executive Director, Head of Supply Chain at Amgen, a biopharmaceutical company, where her responsibilities included leadership of commercial manufacturing and technical operations. Ms. Murphy also held numerous technical and operational roles during her time at Amgen from 2001 to 2015 where she contributed significantly to various facility start-ups, business development integrations, strategic transformations and new product introductions. Prior to Amgen, Ms. Murphy held a variety of process development and engineering positions at Immunex Pharmaceuticals and the Monsanto Company.- Nicole Murphy，自2022年2月起担任Biogen Inc.制药运营和技术执行副总裁。在此之前，Murphy女士曾在Biogen担任高级管理职务，最近于2019年6月至2022年1月担任Biogen Inc.高级副总裁兼全球制造与技术运营主管。2017年，Murphy女士在Biogen血友病专营权的成功分拆过程中发挥了关键作用，担任Bioverativ的副总裁兼技术运营主管，负责临床和商业开发、质量、监管、制造和采购。在分拆之前，Murphy女士于2015年5月至2016年12月担任百健公司的总经理兼剑桥网站运营主管。在加入Biogen之前，Murphy女士是生物制药公司Amgen的执行董事兼供应链主管，她的职责包括领导商业制造和技术运营。2001-2015年，Murphy女士在安进任职期间还担任过许多技术和业务职务，为各种设施初创企业、业务发展整合、战略转型和新产品推出做出了重大贡献。在加入安进公司之前，Murphy女士在Immunex制药公司和孟山都公司担任过各种工艺开发和工程职位。学历：Massachusetts Amherst大学B.S. Engineering分校，工学学士；伦斯勒理工学院，工学硕士，工商管理硕士。
- Nicole Murphy,has served as Biogen Inc. Executive Vice President, Pharmaceutical Operations and Technology since February 2022. Prior to that, Ms. Murphy has held senior executive positions at Biogen, including most recently as Biogen Inc. Senior Vice President, Head of Global Manufacturing & Technical Operations, from June 2019 to January 2022. In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen's hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ responsible for clinical and commercial development, quality, regulatory, manufacturing and procurement. Prior to the spin-off Ms. Murphy was the General Manager and Head of Cambridge Site Operations at Biogen from May 2015 to December 2016. Prior to joining Biogen, Ms. Murphy was Executive Director, Head of Supply Chain at Amgen, a biopharmaceutical company, where her responsibilities included leadership of commercial manufacturing and technical operations. Ms. Murphy also held numerous technical and operational roles during her time at Amgen from 2001 to 2015 where she contributed significantly to various facility start-ups, business development integrations, strategic transformations and new product introductions. Prior to Amgen, Ms. Murphy held a variety of process development and engineering positions at Immunex Pharmaceuticals and the Monsanto Company.
- Priya Singhal
Priya Singhal，医学博士，硕士经验Singhal博士自2023年1月起担任Biogen Inc.执行副总裁兼开发部主管。在此之前，Singhal博士自2021年起担任Biogen Inc.临时研发主管，自2020年重新加入Biogen以来，她还担任包括中国和日本研发在内的全球安全和监管科学主管。Singhal博士最初于2012年至2018年在Biogen任职，历任临床试验效益风险管理副总裁、安全和效益风险管理全球主管、全球发展临时联席主管和高级副总裁等职位。在2020年重返Biogen之前，Singhal博士曾于2019年至2020年在Zafgen Inc.担任研发和制造主管。2008年至2012年，Singhal博士在Vertex制药公司任职，包括医疗事务副总裁。Singhal博士于2005年在Millennium Pharmaceuticals，Inc.开始了她的药物开发生涯，并领导了Velcade和其他化合物的效益风险管理。教育：哈佛公共卫生学院，国际卫生Mumbaii大学硕士，医学博士（医学博士）。
Priya Singhal,has served as Biogen Inc. Executive Vice President and Head of Development since January 2023. Prior to that Dr. Singhal served as Biogen Inc. Interim Head of Research and Development since 2021 in addition to serving as Head of Global Safety and Regulatory Sciences, including China and Japan Research and Development, since rejoining Biogen in 2020. Dr. Singhal was initially at Biogen from 2012 to 2018 and served in positions of increasing seniority as Vice President Clinical Trials Benefit-Risk Management, Global Head of Safety and Benefit Risk Management and as the Interim Co-lead and Senior Vice President of Global Development. Prior to her 2020 return to Biogen, Dr. Singhal served as Head of Research and Development and Manufacturing at Zafgen Inc. from 2019 to 2020. From 2008 to 2012 Dr. Singhal held roles at Vertex Pharmaceuticals, including Vice President, Medical Affairs. Dr. Singhal began her drug-development career at Millennium Pharmaceuticals, Inc. in 2005 and led benefit-risk management for Velcade and other compounds.- Priya Singhal，医学博士，硕士经验Singhal博士自2023年1月起担任Biogen Inc.执行副总裁兼开发部主管。在此之前，Singhal博士自2021年起担任Biogen Inc.临时研发主管，自2020年重新加入Biogen以来，她还担任包括中国和日本研发在内的全球安全和监管科学主管。Singhal博士最初于2012年至2018年在Biogen任职，历任临床试验效益风险管理副总裁、安全和效益风险管理全球主管、全球发展临时联席主管和高级副总裁等职位。在2020年重返Biogen之前，Singhal博士曾于2019年至2020年在Zafgen Inc.担任研发和制造主管。2008年至2012年，Singhal博士在Vertex制药公司任职，包括医疗事务副总裁。Singhal博士于2005年在Millennium Pharmaceuticals，Inc.开始了她的药物开发生涯，并领导了Velcade和其他化合物的效益风险管理。教育：哈佛公共卫生学院，国际卫生Mumbaii大学硕士，医学博士（医学博士）。
- Priya Singhal,has served as Biogen Inc. Executive Vice President and Head of Development since January 2023. Prior to that Dr. Singhal served as Biogen Inc. Interim Head of Research and Development since 2021 in addition to serving as Head of Global Safety and Regulatory Sciences, including China and Japan Research and Development, since rejoining Biogen in 2020. Dr. Singhal was initially at Biogen from 2012 to 2018 and served in positions of increasing seniority as Vice President Clinical Trials Benefit-Risk Management, Global Head of Safety and Benefit Risk Management and as the Interim Co-lead and Senior Vice President of Global Development. Prior to her 2020 return to Biogen, Dr. Singhal served as Head of Research and Development and Manufacturing at Zafgen Inc. from 2019 to 2020. From 2008 to 2012 Dr. Singhal held roles at Vertex Pharmaceuticals, including Vice President, Medical Affairs. Dr. Singhal began her drug-development career at Millennium Pharmaceuticals, Inc. in 2005 and led benefit-risk management for Velcade and other compounds.
- Jane Grogan
Jane Grogan，自2023年9月起担任Biogen Inc.执行副总裁兼开发主管。Grogan博士最近于2021-2023年在Graphite Bio担任首席科学官，于2019-2021年在ArsenalBio担任首席科学官，这两家公司都是细胞和基因治疗公司。从2004年到2019年，Grogan博士在基因泰克的免疫学和免疫肿瘤学领域担任过多个职位，负责提高资历，涵盖类风湿性关节炎、狼疮、MS、炎症性肠病和癌症领域的研究策略和药物开发。
Jane Grogan,has served as Biogen Inc. Executive Vice President and Head of Development since September 2023. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio from 2021 to 2023 and ArsenalBio from 2019 to 2021, both cell and gene therapy companies. From 2004 to 2019 Dr. Grogan held several roles in increasing seniority at Genentech across Immunology and Immuno-oncology, covering research strategies and drug development across Rheumatoid Arthritis, Lupus, MS, Inflammatory Bowel Disease and Cancer.- Jane Grogan，自2023年9月起担任Biogen Inc.执行副总裁兼开发主管。Grogan博士最近于2021-2023年在Graphite Bio担任首席科学官，于2019-2021年在ArsenalBio担任首席科学官，这两家公司都是细胞和基因治疗公司。从2004年到2019年，Grogan博士在基因泰克的免疫学和免疫肿瘤学领域担任过多个职位，负责提高资历，涵盖类风湿性关节炎、狼疮、MS、炎症性肠病和癌症领域的研究策略和药物开发。
- Jane Grogan,has served as Biogen Inc. Executive Vice President and Head of Development since September 2023. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio from 2021 to 2023 and ArsenalBio from 2019 to 2021, both cell and gene therapy companies. From 2004 to 2019 Dr. Grogan held several roles in increasing seniority at Genentech across Immunology and Immuno-oncology, covering research strategies and drug development across Rheumatoid Arthritis, Lupus, MS, Inflammatory Bowel Disease and Cancer.
- Adam Keeney
Adam Keeney，自2023年4月起担任Biogen Inc.执行副总裁兼企业发展主管。Keeney博士最近担任NodThera的首席执行官，NodThera是一家临床阶段的生物技术公司，2018年至2022年专注于慢性炎症。在加入NodThera之前，Keeney博士于2014年至2018年在赛诺菲任职，负责赛诺菲 Gezyme的所有业务发展活动，包括跨治疗领域和模式的早期和后期交易，成功完成了几笔重大交易。从2004年到2013年，Keeney博士曾在强生工作，担任过多个责任越来越大的业务发展职务，并在Lundbeck以发现科学家的身份开始了他的职业生涯。
Adam Keeney,has served as Biogen Inc. Executive Vice President and Head of Corporate Development since April 2023.Dr. Keeney most recently served as the Chief Executive Officer of NodThera, a clinical stage biotech company focused on chronic inflammation from 2018 to 2022. Prior to NodThera, Dr. Keeney was at Sanofi from 2014 to 2018 where he had responsibility for all of Sanofi Gezyme's business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. From 2004 to 2013 Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.- Adam Keeney，自2023年4月起担任Biogen Inc.执行副总裁兼企业发展主管。Keeney博士最近担任NodThera的首席执行官，NodThera是一家临床阶段的生物技术公司，2018年至2022年专注于慢性炎症。在加入NodThera之前，Keeney博士于2014年至2018年在赛诺菲任职，负责赛诺菲 Gezyme的所有业务发展活动，包括跨治疗领域和模式的早期和后期交易，成功完成了几笔重大交易。从2004年到2013年，Keeney博士曾在强生工作，担任过多个责任越来越大的业务发展职务，并在Lundbeck以发现科学家的身份开始了他的职业生涯。
- Adam Keeney,has served as Biogen Inc. Executive Vice President and Head of Corporate Development since April 2023.Dr. Keeney most recently served as the Chief Executive Officer of NodThera, a clinical stage biotech company focused on chronic inflammation from 2018 to 2022. Prior to NodThera, Dr. Keeney was at Sanofi from 2014 to 2018 where he had responsibility for all of Sanofi Gezyme's business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. From 2004 to 2013 Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.
- Susan H. Alexander
Susan H. Alexander，经验丰富，Alexander女士自2018年4月起担任Biogen Inc.执行副总裁、首席法务官兼秘书。在此之前，Alexander女士于2017年3月至2018年3月担任Biogen Inc.执行副总裁、首席法律、企业服务兼秘书，于2011年12月至2017年3月担任Biogen Inc.执行副总裁、首席法律官兼秘书，于2006年至2011年12月担任Biogen Inc.执行副总裁、总法律顾问兼公司秘书。在加入Biogen之前，Alexander女士曾于2003年至2006年1月担任生物制药服务公司Parexel International Corporation的高级副总裁、总法律顾问和公司秘书。2001年至2003年，Alexander女士担任软件公司IONA Technologies的总法律顾问。1995年至2001年，Alexander女士在Cabot Corporation一家特殊化学品和性能材料公司担任法律顾问。在此之前，Alexander女士是Hinckley，Allen & Snyder和Fine & Ambrogne律师事务所的合伙人。教育：韦尔斯利学院学士，波士顿大学法学院，法学博士。
Susan H. Alexander,has served as Biogen Inc. Executive Vice President, Chief Legal Officer since April 2018. Prior to that, Ms. Alexander served as Biogen Inc. Executive Vice President, Chief Legal and Corporate Services from March 2017 to March 2018, as Biogen Inc. Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as Biogen Inc. Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.- Susan H. Alexander，经验丰富，Alexander女士自2018年4月起担任Biogen Inc.执行副总裁、首席法务官兼秘书。在此之前，Alexander女士于2017年3月至2018年3月担任Biogen Inc.执行副总裁、首席法律、企业服务兼秘书，于2011年12月至2017年3月担任Biogen Inc.执行副总裁、首席法律官兼秘书，于2006年至2011年12月担任Biogen Inc.执行副总裁、总法律顾问兼公司秘书。在加入Biogen之前，Alexander女士曾于2003年至2006年1月担任生物制药服务公司Parexel International Corporation的高级副总裁、总法律顾问和公司秘书。2001年至2003年，Alexander女士担任软件公司IONA Technologies的总法律顾问。1995年至2001年，Alexander女士在Cabot Corporation一家特殊化学品和性能材料公司担任法律顾问。在此之前，Alexander女士是Hinckley，Allen & Snyder和Fine & Ambrogne律师事务所的合伙人。教育：韦尔斯利学院学士，波士顿大学法学院，法学博士。
- Susan H. Alexander,has served as Biogen Inc. Executive Vice President, Chief Legal Officer since April 2018. Prior to that, Ms. Alexander served as Biogen Inc. Executive Vice President, Chief Legal and Corporate Services from March 2017 to March 2018, as Biogen Inc. Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as Biogen Inc. Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
- Michael R. McDonnell
Michael R. McDonnell自2005年起担任董事，也是Intelsat, S.A.（一家全球多元化卫星服务的提供商）的财务总监和首席执行官。在2008年11月担任此职位之前，McDonnell先生是MCG Capital 公司（MCG Capital Corporation，（Nasdaq： MCGC），一家财务服务公司，给中型市场公司提供财务和咨询服务的运营总监和财务总监（2006年-2008年11月）。2004-2006年他担任MCG的执行副总裁和财务总监。2000-2004年他担任EchoStar Communications公司（EchoStar Communications Corporation，（Nasdaq： DISH））的财务总监；1986-2000年他在PricewaterhouseCoopers有限责任合伙公司（PricewaterhouseCoopers LLP）工作，1996年担任合伙人。
Michael R. McDonnell,has served as Biogen Inc. Executive Vice President and Chief Financial Officer since August 2020. Prior to joining Biogen, Mr. McDonnell served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, from December 2015 until July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat, a leading global provider of satellite services, from November 2008 to December 2015, as Executive Vice President and Chief Financial Officer of MCG Capital Corporation, a publicly-held commercial finance company, from September 2004 until October 2008 and as MCG Capital Corporation's Chief Operating Officer from August 2006 until October 2008. Before joining MCG Capital Corporation, Mr. McDonnell served as Executive Vice President and Chief Financial Officer for EchoStar Communications Corporation (f/k/a DISH Network Corporation), a direct-to-home satellite television operator, from July 2004 until August 2004 and as its Senior Vice President and Chief Financial Officer from August 2000 to July 2004. Mr. McDonnell spent 14 years at PricewaterhouseCoopers LLP, including 4 years as a partner. Mr. McDonnell is a licensed certified public accountant (CPA).- Michael R. McDonnell自2005年起担任董事，也是Intelsat, S.A.（一家全球多元化卫星服务的提供商）的财务总监和首席执行官。在2008年11月担任此职位之前，McDonnell先生是MCG Capital 公司（MCG Capital Corporation，（Nasdaq： MCGC），一家财务服务公司，给中型市场公司提供财务和咨询服务的运营总监和财务总监（2006年-2008年11月）。2004-2006年他担任MCG的执行副总裁和财务总监。2000-2004年他担任EchoStar Communications公司（EchoStar Communications Corporation，（Nasdaq： DISH））的财务总监；1986-2000年他在PricewaterhouseCoopers有限责任合伙公司（PricewaterhouseCoopers LLP）工作，1996年担任合伙人。
- Michael R. McDonnell,has served as Biogen Inc. Executive Vice President and Chief Financial Officer since August 2020. Prior to joining Biogen, Mr. McDonnell served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, from December 2015 until July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat, a leading global provider of satellite services, from November 2008 to December 2015, as Executive Vice President and Chief Financial Officer of MCG Capital Corporation, a publicly-held commercial finance company, from September 2004 until October 2008 and as MCG Capital Corporation's Chief Operating Officer from August 2006 until October 2008. Before joining MCG Capital Corporation, Mr. McDonnell served as Executive Vice President and Chief Financial Officer for EchoStar Communications Corporation (f/k/a DISH Network Corporation), a direct-to-home satellite television operator, from July 2004 until August 2004 and as its Senior Vice President and Chief Financial Officer from August 2000 to July 2004. Mr. McDonnell spent 14 years at PricewaterhouseCoopers LLP, including 4 years as a partner. Mr. McDonnell is a licensed certified public accountant (CPA).
- Ginger Gregory
Ginger Gregory，经验丰富的博士Gregory博士自2017年7月起担任Biogen Inc.执行副总裁兼首席人力资源官。在加入Biogen之前，Gregory博士于2014年2月至2017年4月在全球专业生物制药公司Shire PLC担任执行副总裁兼首席人力资源官。在此之前，Gregory博士曾在多个各行各业的跨国公司担任高管级别的人力资源职位，包括餐饮控股公司Dunkin ' Brands Group Inc.，在制药公司Novartis AG担任首席人力资源官，在制药公司诺华疫苗和诊断、诺华消费者健康和诺华生物医学研究所以及制药公司Novo Nordisk A/S担任人力资源部门负责人，并在公司总部丹麦Copenhagen担任企业人事与组织高级副总裁。在她职业生涯的早期，Gregory博士在制药公司BMS担任过各种人力资源通才和专家职位，并在信息技术咨询公司Booz Allen & Hamilton担任组织变革和效率领域的顾问。教育，Massachusetts，心理学学士；乔治华盛顿大学，心理学博士。
Ginger Gregory,has served as Biogen Inc. Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin' Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness.- Ginger Gregory，经验丰富的博士Gregory博士自2017年7月起担任Biogen Inc.执行副总裁兼首席人力资源官。在加入Biogen之前，Gregory博士于2014年2月至2017年4月在全球专业生物制药公司Shire PLC担任执行副总裁兼首席人力资源官。在此之前，Gregory博士曾在多个各行各业的跨国公司担任高管级别的人力资源职位，包括餐饮控股公司Dunkin ' Brands Group Inc.，在制药公司Novartis AG担任首席人力资源官，在制药公司诺华疫苗和诊断、诺华消费者健康和诺华生物医学研究所以及制药公司Novo Nordisk A/S担任人力资源部门负责人，并在公司总部丹麦Copenhagen担任企业人事与组织高级副总裁。在她职业生涯的早期，Gregory博士在制药公司BMS担任过各种人力资源通才和专家职位，并在信息技术咨询公司Booz Allen & Hamilton担任组织变革和效率领域的顾问。教育，Massachusetts，心理学学士；乔治华盛顿大学，心理学博士。
- Ginger Gregory,has served as Biogen Inc. Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin' Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness.